gentamicin and vancomycin

Additive nephrotoxicity and ototoxicity: both aminoglycosides (gentamicin) and glycopeptides (vancomycin) accumulate in the renal proximal tubule and in the cochlea/vestibular apparatus. Concurrent administration increases the risk of acute kidney injury and irreversible hearing loss, especially in patients with pre-existing renal impairment or those receiving other nephrotoxic agents.

Combined use raises the risk of nephrotoxicity (rising serum creatinine, reduced urine output, electrolyte disturbances) and ototoxicity (tinnitus, hearing loss, vertigo). The risk is dose- and duration-dependent, and is amplified by dehydration, sepsis, and concomitant use of other nephrotoxins such as NSAIDs or loop diuretics.

Avoid the combination if possible. If co-prescription is necessary, monitor renal function (serum creatinine, urea, electrolytes, urine output) at least daily. Consider therapeutic drug monitoring for both agents, and adjust doses according to renal function. Ensure adequate hydration and consider alternative antibiotics, extended-interval aminoglycoside dosing, or shorter courses of therapy.

Well-established from numerous clinical studies and case reports. Additive nephrotoxicity and ototoxicity are recognised adverse effects when aminoglycosides and glycopeptides are co-administered. Published evidence supports careful monitoring and avoidance in high-risk patients.